Clinical trials demonstrated significant reduction in annualized bleeding rates.
HEMLIBRA significantly reduced treated and spontaneous bleeding episodes in patients with and without factor VIII inhibitors. Most patients achieved zero bleeds, supporting its efficacy as a prophylactic treatment in hemophilia A.

